Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139824 · ClinicalTrials.gov registry record · Phase 1
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
A Phase 1 study of Gout and Hyperuricemia, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04139824 is a Phase 1 study of Gout and Hyperuricemia that has completed, run by LG Chem. The registered enrollment target is 24 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04139824, a Phase 1 study of Gout and Hyperuricemia, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in combination in healthy subjects.
Conditions Studied
Interventions
- DRUG Xanthine Oxidase Inhibitor
- DRUG nonsteroidal anti-inflammatory drug
Study Locations (1)
Texas
- PPD - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139824
The ClinicalTrials.gov registry entry for NCT04139824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Xanthine Oxidase Inhibitor is the first listed.
NCT04139824 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04139824 about?
NCT04139824 is a clinical study titled "The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults". This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in combination in healthy subjects.
What is the current status of trial NCT04139824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-01-22. Estimated completion is 2020-02-25.
What conditions does trial NCT04139824 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia.
What interventions are being tested in trial NCT04139824?
The interventions under investigation include: Xanthine Oxidase Inhibitor (DRUG), nonsteroidal anti-inflammatory drug (DRUG).
Who is sponsoring clinical trial NCT04139824?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04139824 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.